CB-2029

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCB-2029
Drug Alias NameCB-2029
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsProctitisHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCanopus BioPharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCanopus BioPharma Inc
Active IndicationsN/A
Inactive IndicationsProctitisHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A